BR112017010440A2 - administração sublingual de riluzol - Google Patents
administração sublingual de riluzolInfo
- Publication number
- BR112017010440A2 BR112017010440A2 BR112017010440A BR112017010440A BR112017010440A2 BR 112017010440 A2 BR112017010440 A2 BR 112017010440A2 BR 112017010440 A BR112017010440 A BR 112017010440A BR 112017010440 A BR112017010440 A BR 112017010440A BR 112017010440 A2 BR112017010440 A2 BR 112017010440A2
- Authority
- BR
- Brazil
- Prior art keywords
- riluzole
- sublingual administration
- sublingual
- sublingual formulation
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção refere-se à administração sublingual de riluzol. em particular, é fornecido um método para o tratamento de um transtorno ou sintoma neuropsiquiátrico por meio de administração de uma formulação sublingual de riluzol. além disso, é descrito um método para aliviar ou reduzir a dor oral usando a formulação sublingual de riluzol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462083068P | 2014-11-21 | 2014-11-21 | |
PCT/US2015/061106 WO2016081466A1 (en) | 2014-11-21 | 2015-11-17 | Sublingual administration of riluzole |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017010440A2 true BR112017010440A2 (pt) | 2017-12-26 |
Family
ID=55077617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017010440A BR112017010440A2 (pt) | 2014-11-21 | 2015-11-17 | administração sublingual de riluzol |
Country Status (14)
Country | Link |
---|---|
US (1) | US20180153862A1 (pt) |
EP (1) | EP3220890A1 (pt) |
JP (1) | JP2017535612A (pt) |
KR (1) | KR20170137030A (pt) |
CN (1) | CN107735077A (pt) |
AU (1) | AU2015350142A1 (pt) |
BR (1) | BR112017010440A2 (pt) |
CA (1) | CA2967659A1 (pt) |
EA (1) | EA201791110A1 (pt) |
IL (1) | IL252283A0 (pt) |
MX (1) | MX2017006454A (pt) |
PH (1) | PH12017500933A1 (pt) |
SG (1) | SG11201703897SA (pt) |
WO (1) | WO2016081466A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
CN106102737B (zh) | 2013-10-22 | 2019-06-14 | 综合医院公司 | 色甘酸衍生物以及成像和治疗的相关方法 |
EP3616686B8 (en) | 2014-11-21 | 2021-06-23 | Biohaven Pharmaceutical Holding Company Ltd. | Sublingual formulation of riluzole |
US9899038B2 (en) | 2016-06-30 | 2018-02-20 | Karen Elaine Khaleghi | Electronic notebook system |
CN109922800B (zh) | 2016-08-31 | 2023-06-13 | 通用医疗公司 | 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞 |
JP7169591B2 (ja) * | 2016-09-15 | 2022-11-11 | スキンテック ライフ サイエンス リミテッド | 皮膚疾患の処置のためのdimの舌下又は頬側の投与 |
US10751345B2 (en) | 2018-02-21 | 2020-08-25 | AI Therapeutics, Inc. | Combination therapy with apilimod and glutamatergic agents |
US10235998B1 (en) * | 2018-02-28 | 2019-03-19 | Karen Elaine Khaleghi | Health monitoring system and appliance |
JP2021521122A (ja) * | 2018-04-09 | 2021-08-26 | ザ ジェネラル ホスピタル コーポレイション | 筋萎縮性側索硬化症および関連障害の治療のための併用療法 |
KR20210024475A (ko) * | 2018-05-27 | 2021-03-05 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 질환 치료를 위한 릴루졸 경구 붕해 정제의 용도 |
CN112584831A (zh) * | 2018-08-16 | 2021-03-30 | 拜奥海芬治疗学有限公司 | 利鲁唑口腔崩解片用于治疗疾病的用途 |
US10559307B1 (en) | 2019-02-13 | 2020-02-11 | Karen Elaine Khaleghi | Impaired operator detection and interlock apparatus |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
US5837287A (en) * | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
FR2787028B1 (fr) * | 1998-12-15 | 2002-10-18 | Aventis Pharma Sa | Utilisation du riluzole dans le traitement des traumatismes acoustiques |
DE60017733T2 (de) * | 1999-06-04 | 2006-01-12 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Verwendung von riluzol zur behandlung multipler sklerose |
US20040077591A1 (en) * | 2002-03-28 | 2004-04-22 | The Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease |
GB0304636D0 (en) * | 2003-02-28 | 2003-04-02 | Britannia Pharmaceuticals Ltd | Pharmaceutical composition for nasal delivery |
EP2228054A1 (en) * | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
JP2011093849A (ja) * | 2009-10-30 | 2011-05-12 | Kissei Pharmaceutical Co Ltd | トラニラストの易溶性粉末吸入製剤 |
US9241933B2 (en) * | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
EA028060B1 (ru) * | 2011-07-13 | 2017-10-31 | Сайтокинетикс, Инк. | Комбинированная терапия бокового амиотрофического склероза |
IN2014DN07989A (pt) * | 2012-03-01 | 2015-05-01 | Pharnext |
-
2015
- 2015-11-17 CN CN201580073646.5A patent/CN107735077A/zh active Pending
- 2015-11-17 US US15/100,162 patent/US20180153862A1/en not_active Abandoned
- 2015-11-17 SG SG11201703897SA patent/SG11201703897SA/en unknown
- 2015-11-17 EA EA201791110A patent/EA201791110A1/ru unknown
- 2015-11-17 WO PCT/US2015/061106 patent/WO2016081466A1/en active Application Filing
- 2015-11-17 KR KR1020177016605A patent/KR20170137030A/ko unknown
- 2015-11-17 CA CA2967659A patent/CA2967659A1/en not_active Abandoned
- 2015-11-17 MX MX2017006454A patent/MX2017006454A/es unknown
- 2015-11-17 BR BR112017010440A patent/BR112017010440A2/pt not_active Application Discontinuation
- 2015-11-17 AU AU2015350142A patent/AU2015350142A1/en not_active Abandoned
- 2015-11-17 EP EP15821185.4A patent/EP3220890A1/en not_active Withdrawn
- 2015-11-17 JP JP2017545857A patent/JP2017535612A/ja active Pending
-
2017
- 2017-05-15 IL IL252283A patent/IL252283A0/en unknown
- 2017-05-19 PH PH12017500933A patent/PH12017500933A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2017535612A (ja) | 2017-11-30 |
PH12017500933A1 (en) | 2017-11-20 |
SG11201703897SA (en) | 2017-06-29 |
MX2017006454A (es) | 2018-03-23 |
EA201791110A1 (ru) | 2017-11-30 |
CA2967659A1 (en) | 2016-05-26 |
EP3220890A1 (en) | 2017-09-27 |
AU2015350142A1 (en) | 2017-06-15 |
KR20170137030A (ko) | 2017-12-12 |
WO2016081466A1 (en) | 2016-05-26 |
CN107735077A (zh) | 2018-02-23 |
US20180153862A1 (en) | 2018-06-07 |
IL252283A0 (en) | 2017-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017010440A2 (pt) | administração sublingual de riluzol | |
BR112017010423A2 (pt) | formulação sublingual de riluzol | |
BR112017007072A2 (pt) | compostos de triazolopiridina e métodos para o tratamento de fibrose cística | |
BR112017011972A2 (pt) | derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais | |
EA201691582A1 (ru) | Новые фармацевтические препараты | |
MX2017014192A (es) | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. | |
TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
MY199091A (en) | Therapeutic compounds | |
BR112016017317A8 (pt) | composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1 | |
BR112017001221A2 (pt) | derivados de indolizina que são aplicáveis a doenças neurodegenerativas | |
BR112017017729A2 (pt) | forma de dosagem oral de liberação controlada de agonista de receptor gaba | |
BR112017007138A2 (pt) | composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto. | |
EA201692278A1 (ru) | Комбинации формотерола и будесонида для лечения хобл | |
PH12016502530A1 (en) | Pharmaceutical compositions comprising dgla and use of same | |
EA201692020A1 (ru) | Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях | |
CL2016000325A1 (es) | Antagonistas de vía para tratar trastornos del sueño por cambio de fase | |
BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
PH12016501483B1 (en) | P-substituted asymmetric ureas and medical uses thereof | |
MX370436B (es) | Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica. | |
BR112017009358A2 (pt) | imunoterapia específica de peptídeo t terapêutico para uso no tratamento de metástase cerebral de um paciente com hla-2 positivo | |
BR112017002449A2 (pt) | tratamento de sintomas associados com terapia de privação androgênica | |
MX2016005645A (es) | Composicion farmaceutica topica de acitretina. | |
BR112016016098A2 (pt) | Compostos orgânicos | |
BR112016019893A2 (pt) | composições de glicoproteína sialilada e seus usos | |
MX2014008336A (es) | Combinacion farmacologica antihiperalgesica, antialodinica y antiinflamatoria, composiciones farmaceuticas que la contienen, y su uso para el tratamiento del dolor neuropatico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |